Table IV.
Univariate analysis | Multivariate analysis | ||||
---|---|---|---|---|---|
|
|
||||
Parameters | Hazard ratio (95% CI) | P-value | Hazard ratio (95% CI) | P-value | AUC |
Age (years) | 1.01 (0.95–1.09) | 0.641 | |||
BMI (kg/m2) | 1.04 (0.88–1.20) | 0.584 | |||
AST (IU/l) | 1.01 (0.99–1.04) | 0.122 | |||
ALT (IU/l) | 1.01 (0.99–1.03) | 0.158 | |||
PLT (x104/μl) | 1.04 (0.94–1.14) | 0.414 | |||
TBil (mg/dl) | 1.45 (0.28–5.22) | 0.593 | |||
Alb (g/dl) | 1.46 (0.42–6.08) | 0.573 | |||
PT (%) | 1.00 (0.95–1.04) | 0.854 | |||
AFP (ng/ml) | 1.00 (1.00–1.00) | 0.019 | 1.00 (1.00–1.00) | 0.125 | |
PIVKA-II (mAU/ml) | 1.00 (1.00–1.00) | 0.012 | 1.00 (0.99–1.00) | 0.387 | |
HbA1c (%) | 0.55 (0.16–1.52) | 0.286 | |||
Diameter of tumor (cm) | 1.19 (1.01–1.42) | 0.033 | 0.93 (0.64–1.20) | 0.620 | |
SUVmax | 1.26 (1.03–1.53) | 0.001 | 1.24 (1.01–1.55) | 0.033 | 0.846 |
CI, confidence interval; AUC, area under the receiver operating characteristic curve; BMI, body mass index; AST, aspartate aminotransferase; ALT, alanine aminotransferase; PLT, platelet count; TBil, total bilirubin; Alb, albumin; PT, prothrombin time; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence or antagonist-II; HbA1c, hemoglobin A1c; SUVmax, maximal standardized uptake value.